Antibacterial Agents TRIZ Cases

Recombinant polypeptides from Candida Als3 and Hyr1 proteins elicit targeted immune responses to reduce mortality rates in high-risk patients.

Tricyclic sulfonamide compounds activate protein phosphatase 2A to treat cancer and restore chemotherapy sensitivity.

Peptides activate guanylate cyclase C to increase upper gastrointestinal motility, alleviating bloating without lower tract side effects.

Conjugating aralkyl ligands to oligonucleotides enhances serum solubility and cellular uptake through intermediary protein binding.

Replacing murine variable regions with human immunoglobulin sequences reduces anti-infliximab antibody formation and unwanted immune reactions in patients.

Modified mannose compounds block type 1 pili interaction with host cell receptors, preventing sub-mucosal infection establishment in inflammatory bowel disease.

MMP9 binding antibodies selectively inhibit the enzyme, avoiding musculoskeletal syndrome caused by broad-spectrum inhibitors.

A monoclonal antibody targets the PcrV protein to inhibit bacterial cytotoxicity.

Acetalization replaces unstable ester linkages to prevent antibiotic resistance.

Anhydrous fusidic acid crystals resolve hemihydrate instability and bioavailability issues via controlled phase transitions.

Alkyl substituted polylactides enable parenteral drug administration through viscous admixing without organic solvents.

Peptides derived from GPI linkage epitopes generate counteracting antibodies that neutralize harmful autoantibodies.

Bacillus-based direct-fed microbials replace antibiotics to treat E. coli infections, reducing antimicrobial resistance while improving animal health.

Cation-exchange chromatography removes angiogenin and LPS contaminants to maintain lactoferrin stability.

Cavity pattern in absorbent adhesive layer enables rapid exudate absorption and faster pain relief without compromising adhesion.

Chemokine-expressing dendritic cells recruit T cells to tumor sites, overcoming limited migration and ineffective intravenous delivery of standard treatments.

Hybrid saccharide-aromatic structures resolve chemical instability and poor absorption trade-offs in natural inhibitors.

Ultrasonic synthesis of a triazole derivative combats antibiotic-resistant bacteria and fungi.

A nanogel vaccine formulation delivers antigens and STING ligands to induce antigen-specific Th1 cells.

Dynamic pirfenidone dosing based on liver enzyme monitoring maintains therapeutic efficacy while preventing hepatotoxicity in fibrosis treatment.

Measuring cholesterol and oxysterol ratios distinguishes latent from active tuberculosis, enabling precise treatment monitoring.

Crystalline forms of CEM-101 provide stable pharmaceutical compositions with consistent solubility profiles.

Segmented macroarray screening identifies cyanopyridine agents effective against resistant bacterial strains.

Synthetic mannosides block bacterial FimH adhesin binding sites, preventing recurrence of urinary tract infections.

VraSR operon inhibitors potentiate beta-lactam antibiotics to overcome methicillin-resistant Staphylococcus aureus resistance.

A high-affinity immunoglobulin targets the anthrax toxin protective antigen to enable sensitive detection and treatment.

Pyrazinoic acid conjugates deliver active metabolites via enzymatic conversion to enhance antibacterial activity against Mycobacterium species.

Specific amino acid substitutions in heavy and light chains improve pharmacokinetics and stability for treating IL-17-mediated diseases.

Selective indazoline inhibitors reduce tumor growth by balancing immune suppression with metabolic homeostasis.

Lectin-conjugated hydratable polymers bind to mucin and absorb water to restore hydration in aging tissues, reducing microbial adhesion.

An inactivated chimeric vaccine replaces Yellow Fever backbone proteins with West Nile virus envelope and pre-membrane sequences to induce protective immunity.

GaPpIX binds cell-surface hemin receptors to deliver targeted photodynamic inactivation against drug-resistant pathogens like MRSA.

Segmented antimicrobial peptides with VGFPV motifs target drug-resistant pathogens while protecting mammalian cells from cytotoxicity.

A non-alcohol mouth rinse forms a clear microemulsion with essential oils using polyols and surfactants.

Compounds inhibit metallo-beta-lactamases by binding zinc ions, restoring beta-lactam efficacy against carbapenem-resistant infections.

Water-soluble polyether replaces carrier liquids in bone cement, eliminating volume expansion and surfactant toxicity during setting.

A lipid-saturated biodegradable polymer matrix enables controlled release of pharmaceutical agents without aqueous solvents.

Boron-based compounds inhibit diverse beta-lactamase enzymes through coordinate covalent bonding, restoring antibiotic efficacy against resistant bacteria.

Lactobacillus plantarum Inducia resolves inconsistent cholesterol reduction by lowering LDL and ox-LDL levels while inhibiting Clostridium difficile.

Tryptophanyl-tRNA synthetase induces neutrophil accumulation to resolve inadequate innate immune activation in infectious inflammatory diseases.

Vitamin E TPGS combined with lipophiles creates a topical gel that inhibits MRSA and MRSP growth while soothing radiation-damaged skin.

Purified obligate lytic bacteriophages reduce lung bacterial burden in Staphylococcus aureus infections without disrupting native gut flora.

Macrocyclic peptides bind PD-L1 to block immune checkpoint interactions, restoring T-cell activity and reducing exhaustion.

Metagenomic sequencing isolates specific oral bacterial strains and bioactive peptides that inhibit cariogenic bacteria, bypassing traditional culture biases.